News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Sunstone Life Science Ventures divests its holding in Arcoma AB
Sunstone announces that one hundred percent of the holding in Arcoma AB have been sold in a structured block sale. Sunstone has been a major owner in Arcoma since 2010 and is proud of what the company has achieved in delivering world-class digital radiographic...
Sunstone Life Science Ventures joins EUR 57 Million Series A Investment in Kynexis to Advance Development of Novel Therapeutics for Cognitive Disorders
Sunstone Life Science Ventures (Sunstone), a leading Nordic venture capital firm, is excited to announce its participation in a EUR 57 million Series A funding round for Kynexis B.V., a pioneering biotech company dedicated to advancing treatments for cognitive...
Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developing a first-in-class regenerative treatment for type 1 diabetes
Sunstone Life Science Ventures (Sunstone), a leading European venture capital firm focused on life science therapeutics, today announced that Sunstone’s Fund IV has invested in the Series A financing round of DiogenX now increased to €33.5 million ($33.8M). Press...
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
MinervaX ApS, a privately held Danish biotechnology company developing a novel, prophylactic vaccine against Group B Streptococcus (GBS), has today announced the completion of a EUR 54 million upsized financing. The financing includes investment from new investors EQT...
IO Biotech, Inc. Announces USD 75 Million Private Placement Financing
IO Biotech, Inc. (Nasdaq: IOBT), a clinical biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, today announced that it has entered into a definitive securities purchase agreement for a private...
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
MinervaX ApS, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announces the first phase 1 clinical study in older adults of its novel GBS vaccine, at CEVAC (Centre for Vaccinology) in Ghent, Belgium. GBS is...